Practical implication If the clinical picture suggests complex connective tissue remodeling, using one peptide alone can underperform
Disclosures: Fatima DAHBOUL: Nothing to Disclose, JIHAN SUN: Nothing to Disclose, Benjamin Buchard: Nothing to Disclose, Delphine Weil-Verhoeven: Nothing to Disclose, Vincent Di Martino: Nothing to Disclose, Aicha Demidem: Nothing to Disclose, Armand Abergel: Nothing to Disclose 1875 RADIOMICS-BASED PREDICTION OF HCC RESPONSE TO ATEZOLIZUMAB/BEVACIZUMAB Isaac Israel Rodriguez Salazar 1 Andreas Teufel 1 Abhinay Vellala 1 Timo Itzel 1 Jimmy Daza 1 Michael Vcha 1 Manuel Debic 2 De-Hua Chang 3 Michael Dill 2 Max Seidensticker 4 Gerd Oswald Stefan Schnberg 1 Lukas Mller 5 Julia Mayerle 4 Stefan Munker 4 Peter Galle 5 Arndt Weinmann 5 Dietmar Tamandl 6 Matthias Pinter 6 Marino Venerito 7 Matthias Ebert 1 Matthias Froelich 1 Maciej Pech 7 Friedrich Sinner 7 Bernhard Scheiner 6 , 1 Medical Faculty Mannheim, 2 Medical Faculty Heidelberg, 3 Cantonal Hospital of Lucerne, 4 LMU Munich, 5 University Medical Center Mainz, 6 Medical Faculty Vienna, 7 Magdeburg University Background: Atezolizumab/ bevacizumab has emerged as a breakthrough therapy for advanced hepatocellular carcinoma (HCC)
Marsman, Do glia provide the link between low-grade systemic inflammation and normal cognitive ageing
Animals received the following treatments for 12 days: 0.9% saline, 100 ng/kg or 10 g/kg BPC 157
Microglial and astrocytic proteins are preferentially elevated in the GCLC-KO mouse brain To uncover mechanisms leading to brain atrophy in GCLC-KO mice, we next performed a comprehensive analysis of protein expression by Liquid Chromatography-Mass spectrometry (LCMS) analysis using brain samples from 4-month-old GCLC-KO mice (Fig
Thymoquinone as a causative allergen in Nigella sativa oil contact dermatitis with cross-reactivity to tert-butylhydroquinone
